REG - GenIP PLC Tekcapital plc - New Product Launch – Invention Validator

TekcapitalAnnouncement

10/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251010:nRSJ8258Ca&default-theme=true

RNS Number : 8258C  GenIP PLC  10 October 2025

 

 

10 October 2025

 

GenIP Plc

("GenIP" or the "Company")

 

New Product Launch - Invention Validator

 

 

GenIP Plc, a technology consultancy providing Generative Artificial
Intelligence (GenAI) services to help research organisations and corporations
commercialise their innovations, is pleased to announce the launch of
'Invention Validator', a premium product designed to test user perception and
adoption readiness of new technological discoveries. The inaugural project is
with a research university in South Africa, focused on evaluating an
agricultural biotechnology innovation.

 

The new service, which is currently being pilot tested, combines GenIP's
established Invention Evaluator report with customised market and validation
research and has an entry price point in excess of $12,000.

 

It works in two steps:

 

1.   a comprehensive evaluation of technical merit, IP strength, and market
potential;

2.   a structured collection and assessment of data from target end-users to
validate adoption readiness.

 

GenIP designed a structured questionnaire, which is being distributed to
farmers who are the end users and target customers for the new technology. The
questionnaire will capture feedback on pricing, adoption barriers, and
purchase intent. The responses will be analysed alongside the Invention
Evaluator report on the technology. GenIP's Invention Validator will deliver
strategic recommendations on commercialization approach, pricing strategy, and
partnership priorities to the technology owner.

 

While the first application targets agriculture, it is anticipated that the
methodology can be applied to various sectors, including medical devices,
renewable energy systems, advanced materials, environmental monitoring tools,
and digital health platforms. Whilst still in pilot launch stage, three
universities in the Republic of Chile have already expressed interest in the
new product, with one already reviewing a proposal. GenIP plans broader
outreach to both corporates and research organisations.

 

The service is designed as a high-margin, replicable offering, building on
GenIP's proprietary technology ranking system already tested and proven from
other consulting work. AI-powered automation reduces consulting overheads
while maintaining the strategic depth expected by our clients.

 

Pricing varies by project scope, number of technologies assessed, and
validation depth required, with all packages including the foundational
Invention Evaluator report.

 

The launch of 'Invention Validator' is the next step in delivering a suite of
new products under GenIP's AI-powered platform, as set out in our recently
announced commercial strategy.

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"This new product marks an important milestone in GenIP's evolution from
delivering standalone reports to becoming an embedded partner in our clients'
commercialization decisions.

 

Many technologies fail because research teams have to choose between slow,
expensive market studies or risky assumptions about user adoption. Invention
Validator bridges that gap by delivering fast, actionable insights by pairing
AI driven analysis with real user feedback.

 

Invention Validator is strategically significant because it builds directly on
our Invention Evaluator foundation. Organizations start with our core report,
then progress naturally to Invention Validator to test real-world adoption.
This progression from evaluation to validation and through to execution,
creates the opportunity for recurring revenues to drive our growth strategy.

 

Universities have been asking for this capability and we have demonstrated
this demand through its inaugural engagement. As we scale Invention Validator,
we are building the high-value, repeatable client journeys that unlock
sustained revenue growth."

 

 

 

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 AlbR Capital Limited (Broker)                                             Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                             cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                               jb@albrcapital.com (mailto:Jb@albrcapital.com)

 Redchurch Communications (Financial PR)                                   genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI
and innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●     Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●     Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLEANENELDSFFA